Up­dat­ed: Tale of two ‘Abs’: Ab­b­Vie part­ners with an­ti­body biotech Ab­Cellera, but keeps de­tails un­der wraps

Ab­b­Vie has signed a mul­ti-year deal with Van­cou­ver-based an­ti­body biotech Ab­Cellera, it an­nounced Thurs­day morn­ing.

How­ev­er, out­side of that, the duo gave few de­tails about their col­lab­o­ra­tion. They did say the deal is good for up to five tar­gets but didn’t say what ar­eas or in­di­ca­tions those tar­gets would be in. When asked, Ab­Cellera CEO Carl Hansen de­clined to give any specifics, of­fer­ing on­ly that “the themes that have led to this in­ter­ac­tion are not that dif­fer­ent from the [ones] un­der­ly­ing the col­lab­o­ra­tions we’ve done with oth­er, I’d say top-en­abled firms across the space, so you know, work with Lil­ly, work with Re­gen­eron.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER